Solid tumours

#Cancer treatment #Intensity Therapeutics #Oncology #Phase II trial #Solid tumours

Intratumoral injection drives local and systemic anti-cancer activity

eBioMedicine, a Lancet Discovery Science journal, has published Intensity Therapeutics’ Phase I/II IT-01 clinical study manuscript for the treatment of metastatic or refractory cancers.   According to the data, in heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following… Read More

#Cancer Research #News

The tumour microenvironment
#Cancer research #Immunotherapy #Solid tumours

MaaT Pharma releases positive results for anti-tumour candidate 

Biotechnology company MaaT Pharma has announced preclinical results for its drug candidate MaaT034, including promising anti-tumour efficacy results and immune activation.  MaaT034, a first-in-class co-cultured full ecosystem product, is designed to optimise intestinal microbiome functions and improve patient responses to immunotherapy in combination with Immune Checkpoint Inhibitors (ICIs).   The… Read More

#Cancer Research #News

Colon cancer
#Colorectal cancer #Larkspur Biosciences #Oncology #Preclinical development #Solid tumours

First degrader of lipid kinase PIP4K2C shows promise in colon cancer

Larkspur Biosciences has announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumours.   The announcement was made at ACS Fall 2025, a meeting of the American Chemical Society in Washington,… Read More

#Cancer Research #News

Funding concept
#Clinical trial #Funding #LIfT BioSciences #Oncology #Solid tumours

LIfT BioSciences receives €12m to support solid tumour trials

LIfT BioSciences has received a grant of €12 million from Ireland’s Disruptive Technologies Innovation Fund (DTIF) to advance its Immuno-Modulatory Alpha Neutrophils (IMANs), designed to overcome treatment resistance in solid tumours, through first-in-human clinical trials expected to start in Q4 2026.  The €12 million grant, the largest… Read More

#Business & Investment #News

#Dispatch Bio #Immunotherapy #Oncology #Solid tumours #Start-ups

Biotech aims to create universal solid tumour therapy

Dispatch Bio has officially launched with a stated mission to engineer a universal treatment across solid tumours.  Immunotherapies have struggled to effectively treat solid tumours due to the lack of a tumour-specific target and the presence of an immune-suppressive tumour microenvironment.   Dispatch’s Flare platform has… Read More

#Business & Investment #Cancer Research #News #Start-up Zone

Tumour microenvironment
#Cancer research #Drug discovery #Insilico Medicine #Solid tumours

First patient receives novel MAT2A inhibitor for solid tumours

The first patient has been dosed in a global multicentre clinical trial to evaluate ISM3412, a potentially best-in-class, MAT2A inhibitor with novel structure, in patients with locally advanced and metastatic solid tumours. The Phase I study consists of two parts: dose escalation and dose selection optimisation, where participants will receive… Read More

#Cancer Research #News

Cancer tumour
#ASCO #Immunotherapy #Oncology #Rice University #Solid tumours #Spinout #Start-ups

Sentinel BioTherapeutics launches at 2025 ASCO Annual Meeting

Biotech venture creation studio RBL has launched Sentinel BioTherapeutics, a spin-out from Rice University, at the 2025 ASCO Annual Meeting.   This is RBL’s first company spin-out since its formation in October 2024 and positions Sentinel to begin preparations ahead of the next phase of clinical development for… Read More

#Business & Investment #News #Start-up Zone

Liver cancer
#Moderna #mRNA #Oncology #Phase I trial #Solid tumours

Pan-tumour antigen therapy candidate enters the clinic

The first US participant has been dosed in Moderna’s Phase I study evaluating mRNA-4106, a novel pan-tumour antigen therapy candidate, in patients with advanced or metastatic solid tumours.  The first dose was administered at START Center for Cancer Research (START) in San Antonio by Dr Amita Patnaik. Read More

#Cancer Research #News

CAR-T cells attacking a cancer cell
#Cancer research #CAR-T #Cell and gene therapy #Leucid Bio #Solid tumours

First patient dosed in CAR-T therapy trial for solid tumours

Leucid Bio has dosed the first patient in the Phase I AERIAL trial evaluating the safety and clinical activity of LEU011 in patients with refractory solid tumours. Initiation of the AERIAL trial follows the successful first close of the Series A1 financing of £7.2 ($9.51) million in February 2025, co-led… Read More

#Cancer Research #News

#Cancer research #Oncology #Solid tumours

New DDW Highlights podcast: 12 May 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our highlights this week demonstrate a variety of approaches to cancer treatment, including a… Read More

#News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Bispecific Antibodies #Cancer research #Solid tumours #SOTIO

The challenges in solid tumour targeting with bispecific ADCs

Czech biotechnology company, SOTIO, recently started preclinical development of its first two bispecific antibody drug conjugates (ADCs), which it says are “just the beginning” of what it has in store for its next-generation ADC pipeline. DDW’s Megan Thomas speaks with SOTIO’s Chief Scientific Officer, Martin Steegmaier, about the company’s pipeline. Read More

#Cancer Research #Exclusive Content

#Cancer research #Oncology #Solid tumours

This week in drug discovery (5-9 May) 

News round-up for 5-9 May by DDW Senior Digital Content Editor Diana Spencer. Our highlights this week demonstrate a variety of approaches to cancer treatment, including a BTK inhibitor, macrophage checkpoint inhibitor, and antibody-drug conjugates, at various stages of development. The top stories:… Read More

#News

Antibody drug conjugate
#AACR #Antibody drug conjugate (ADC) #Oncology #Solid tumours #SOTIO

ADCs show best-in-class potential for treating solid tumours

SOTIO Biotech has presented preclinical data on two of its leading antibody-drug conjugate (ADC) candidates, SOT109 and SOT106, demonstrating strong anti-tumour activity and favourable tolerability profiles across multiple tumour models.  The data shared at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL supports… Read More

#Cancer Research #News

Liver cancer
#Macrophages #Oncology #Phase I trial #Pheast Therapeutics #Solid tumours

First patient receives anti-CD24 macrophage checkpoint inhibitor

Pheast Therapeutics has treated the first patient in its Phase I clinical trial evaluating PHST001, an anti-CD24 macrophage checkpoint inhibitor, in patients with advanced solid tumours.  The study will enrol up to 80 patients with advanced relapsed and/or refractory solid tumours.  The study’s primary objectives… Read More

#Cancer Research #News #Trending News

Immunotherapy
#Cancer research #Candel Therapeutics #Immunotherapy #Solid tumours

Gene delivery evolution: Advancing novel cancer immunotherapies

DDW Editor Megan Thomas speaks to Paul Peter Tak, President and CEO of Candel Therapeutics, about the company’s cancer data and its development of next-generation viral immunotherapies targeting solid tumours. MT: Please provide a brief overview of Candel’s pipeline? PT: Candel’s clinical stage pipeline is built on two distinct multimodal… Read More

#Cancer Research #Exclusive Content